MEDICAL REGULATIONS 11 Edition - FIVB
MEDICAL REGULATIONS 11 Edition - FIVB
MEDICAL REGULATIONS 11 Edition - FIVB
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>FIVB</strong> Medical Regulations – <strong>11</strong>th <strong>Edition</strong><br />
should be considered an Adverse Analytical Finding, <strong>FIVB</strong> shall pursue<br />
the matter in accordance with Article 7.1.3.<br />
7.2.5 The <strong>FIVB</strong> will not provide notice of an Atypical Finding until it<br />
has completed its investigation and has decided whether it will bring<br />
the Atypical Finding forward as an Adverse Analytical Finding unless<br />
one of the following circumstances exists:<br />
(a) If the <strong>FIVB</strong> determines the B Sample should be analyzed<br />
prior to the conclusion of its follow-up investigation, it may conduct the<br />
B Sample analysis after notifying the Athlete, with such notice to<br />
include a description of the Atypical Finding and the information<br />
described in Article 7.1.3(c) to (f).<br />
(b) If the <strong>FIVB</strong> receives a request, either from a Major Event<br />
Organization shortly before one of its International Events or from a<br />
sports organization responsible for meeting an imminent deadline for<br />
selecting team members for an International Event, to disclose whether<br />
any Athlete identified on a list provided by the Major Event<br />
Organization or sports organization has a pending Atypical Finding,<br />
<strong>FIVB</strong> shall so identify any such Athlete after first providing notice of the<br />
Atypical Finding to the Athlete.<br />
7.3 Results Management for for Tests Initiated During Other<br />
International Events<br />
Results management and the conduct of hearings from Tests Initiated during<br />
Other International Events, by the International Olympic Committee, the<br />
International Paralympics Committee, or a Major Event Organization, shall be<br />
managed, as far as sanctions beyond Disqualification from the Event or the<br />
results of the Event, by the <strong>FIVB</strong>.<br />
7.4 Results Management for Tests Initiated by National Federations<br />
Results management conducted by National Federations for Tests initiated by<br />
them shall be consistent with the general principles for effective and fair results<br />
management which underlie the detailed provisions set forth in Article 7. Results<br />
of all Doping Controls shall be reported to the <strong>FIVB</strong> and to WADA within 14 days<br />
of the conclusion of the National Federation's results management process. Any<br />
apparent anti-doping rule violation by an Athlete who is a member of that National<br />
Federation shall be promptly referred to an appropriate hearing panel established<br />
pursuant to the rules of the National Federation or national law. Apparent antidoping<br />
rule violations by Athletes who are members of another National<br />
Federation shall be referred to the Athlete's National Federation for hearing.<br />
7.5 Results Management for Whereabouts Violations<br />
7.5.1 Results management in respect of an apparent Filing Failure<br />
by an Athlete in <strong>FIVB</strong>’s Registered Testing Pool shall be conducted by<br />
<strong>FIVB</strong> in accordance with Article <strong>11</strong>.6.2 of the International Standard for<br />
Testing (unless it has been agreed in accordance with Article 5.5.4 that<br />
the National Federation or National Anti-Doping Organization shall take<br />
such responsibility).<br />
- 16 -